The latest developments from suppliers of ingredients, development and manufacturing services, and related technologies for pharmaceutical and biopharmaceutical development and production.
Catalent Pharma Solutions has agreed to collaborate with Valerius Biopharma AG, a Basel Switzerland-headquartered biopharmaceutical company focused on biosimilars, to develop and manufacture Valerius’ biosimilar products.
Under the agreement,...
AGC Biologics, a Bothell, Washington-headquartered contract development and manufacturing organization of biologics, reports on its commercial supply agreement with MacroGenics, a Rockville, Maryland-based clinical-stage biopharmaceutical company,...
Evotec AG, a Hamburg, Germany-based drug discovery and development company, has formed a collaboration with Carna Biosciences, a Kobe, Japan-based biopharmaceutical company, to use Evotec's INDiGO platform to develop Carna’s investigational blood...
AMRI, a contract research, development, and manufacturing organization, has launched a new multipurpose aseptic active pharmaceutical ingredient (API) line at the company’s facility in Valladolid, Spain.
The line, which was officially opened May...
Lonza has extended its contract with Proteon Therapeutics, a Waltham, Massachusetts-headquartered company developing therapeutics for kidney and vascular diseases, to commercially supply the active pharmaceutical ingredient (API) of Proteon’s lead...
Sterling Pharma Solutions, a Dudley, UK-headquartered contract development and manufacturing organization, is investing £6 million ($8 million) to expand its pilot plant at its UK site to increase capacity by 33% and enhance the site’s production...
Lonza is investing in mid-scale mammalian cell biomanufacturing capacity and new cell-therapy suites at its site in Portsmouth, New Hampshire.
Lonza plans to install multiple 6,000-liter bioreactors at the site with building expected to...
Almac Group, a Craigavon, UK-based contract development and manufacturing organization (CDMO) of active pharmaceutical ingredients (APIs) and drug products, has appointed David Taylor as Head of Manufacturing Operations. Taylor joined the Almac...
CordenPharma, a contract development and manufacturing organization of active pharmaceutical ingredients (APIs) and drug products, has expanded its commercial oligonucleotide API manufacturing at its CordenPharma Colorado site in Boulder,...
Catalent Pharma Solutions has made leadership changes within its biologics business. The changes follows its $950-million acquisition in 2017 of Cook Pharmica, a Bloomington, Indiana contract development and manufacturing organization of biologic...
Camargo Pharmaceutical Services, a Cincinnati, Ohio-based provider of drug-development services, including 505(b)(2) drug development and global equivalents, has appointed Daniel S. Duffy as the firm’s new Chief Executive Officer. Kenneth V....
WuXi Biologics, part of WuXi AppTec, a contract service provider, plans to invest EUR 325 million ($392 million) in a new biologics drug-substance manufacturing facility in Mullagharlin, Dundalk, County Louth, Ireland.
The company says the...
Avid Bioservices, a Tustin, California-based contract development and manufacturing organization (CDMO) of biopharmaceutical products derived from mammalian cell culture and a wholly owned subsidiary of Peregrine Pharmaceuticals, has provided an...
STA Pharmaceutical, a subsidiary of WuXi AppTec, has signed an investment agreement with the government of Shanghai, Jinshan District, China to build a new research & development (R&D) center.
The new facility will support WuXi STA’s...
Cell and Gene Therapy Catapult (CGT Catapult), a center of excellence funded by Innovate UK, the UK government’s innovation agency, to support cell-therapy organizations, has opened a cell- and gene- therapy manufacturing center in Stevenage,...
